Literature DB >> 12056720

Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in-vitro maturation and in-vivo remodeling.

Elena Rabkin1, Simon P Hoerstrup, Masanori Aikawa, John E Mayer, Frederick J Schoen.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Contemporary tissue valves are non-viable, and unable to grow, repair or remodel. It was postulated that tissue-engineered heart valves (TEHV) fabricated from autologous cells and a biodegradable scaffold could yield a dynamic progression of cell phenotype and extracellular matrix (ECM), in vitro and in vivo, and ultimately recapitulate native valve microscopic architecture.
METHODS: Trileaflet valve constructs were fabricated from poly-4-hydroxybutyrate-coated polyglycolic acid seeded with ovine endothelial and carotid artery medial cells, cultured in vitro for 4-14 days in a pulse duplicator, implanted as pulmonary valves in five lambs, and explanted at 4-20 weeks. ECM composition and collagen architecture were examined by histology (including Movat pentachrome stain and picrosirius red under polarized light), and cell phenotype by immunohistochemistry.
RESULTS: Cells from in-vitro constructs (14 days) were activated myofibroblasts, with strong expression of alpha-actin (microfilaments), vimentin (intermediate filaments) and SMemb (non-muscle myosin produced by activated mesenchymal cells). Cells from in-vivo explants at 16-20 weeks were fibroblast-like, with predominant vimentin expression and undetectable levels of alpha-actin (similar to native valve). Collagen elaboration and cellular expression of MMP-13 (collagenase 3) were evident in vitro at 14 days. In-vivo explants had increased collagen accumulation and strong MMP-13 expression at 4-8 weeks, but less activation (decreased expression of SMemb) and patchy endothelial cells at 16-20 weeks. Moreover, the ECM architecture of 16- to 20-week explanted TEHV resembled that of native valves.
CONCLUSION: Cell phenotype and ECM in TEHV prepared in vitro and implanted in vivo are dynamic, and reflect the ability of a vital tissue to remodel and, potentially, to grow.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056720

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  29 in total

Review 1.  Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices.

Authors:  Dörthe Schmidt; Ulrich A Stock; Simon P Hoerstrup
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

Review 2.  Heart valve function: a biomechanical perspective.

Authors:  Michael S Sacks; Ajit P Yoganathan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

3.  A novel flex-stretch-flow bioreactor for the study of engineered heart valve tissue mechanobiology.

Authors:  George C Engelmayr; Lorenzo Soletti; Sarah C Vigmostad; Stephanus G Budilarto; William J Federspiel; Krishnan B Chandran; David A Vorp; Michael S Sacks
Journal:  Ann Biomed Eng       Date:  2008-02-06       Impact factor: 3.934

Review 4.  Tissue engineering on matrix: future of autologous tissue replacement.

Authors:  Benedikt Weber; Maximilian Y Emmert; Roman Schoenauer; Chad Brokopp; Laura Baumgartner; Simon P Hoerstrup
Journal:  Semin Immunopathol       Date:  2011-01-29       Impact factor: 9.623

Review 5.  Heart Valve Biomechanics and Underlying Mechanobiology.

Authors:  Salma Ayoub; Giovanni Ferrari; Robert C Gorman; Joseph H Gorman; Frederick J Schoen; Michael S Sacks
Journal:  Compr Physiol       Date:  2016-09-15       Impact factor: 9.090

6.  Laser microfabricated poly(glycerol sebacate) scaffolds for heart valve tissue engineering.

Authors:  Nafiseh Masoumi; Aurélie Jean; Jeffrey T Zugates; Katherine L Johnson; George C Engelmayr
Journal:  J Biomed Mater Res A       Date:  2012-07-24       Impact factor: 4.396

Review 7.  Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification.

Authors:  Sophie E P New; Elena Aikawa
Journal:  Circ Res       Date:  2011-05-27       Impact factor: 17.367

Review 8.  Serotonin receptors and heart valve disease--it was meant 2B.

Authors:  Joshua D Hutcheson; Vincent Setola; Bryan L Roth; W David Merryman
Journal:  Pharmacol Ther       Date:  2011-04-02       Impact factor: 12.310

9.  Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis.

Authors:  Paolo Poggio; Rachana Sainger; Emanuela Branchetti; Juan B Grau; Eric K Lai; Robert C Gorman; Michael S Sacks; Alessandro Parolari; Joseph E Bavaria; Giovanni Ferrari
Journal:  Cardiovasc Res       Date:  2013-03-12       Impact factor: 10.787

10.  Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves.

Authors:  Virna L Sales; Bret A Mettler; George C Engelmayr; Elena Aikawa; Joyce Bischoff; David P Martin; Alexis Exarhopoulos; Marsha A Moses; Frederick J Schoen; Michael S Sacks; John E Mayer
Journal:  Tissue Eng Part A       Date:  2010-01       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.